ArticleTranslational lung cancer research2021

A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401).

Masaaki Okajima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.